Nature's Way

Nature's Way Umcka Cold & Flu Orange 20 Chewable

Nature's Way

Nature's Way Umcka Cold & Flu Orange 20 Chewable

Barcode: 033674151617
Size: 20
Form: Chewable

Umcka Cold & Flu Orange 20 Chewable

Why Umcka ColdFlu?

Sometimes youre not sure if its a cold or flu. Cold and flu symptoms can be so similar, it can be difficult to determine the cause of your discomfort. Umcka ColdFlu formulas combine two clinically-effective natural medicines Umcka P. sidoides and the Alpha CF blend to tackle both cold and flu.

Why Umcka ColdFlu Orange Chewable?

Convenient tablets Umcka ColdFlu Orange Chewable Tablets combines Pelargonium sidoides EPs 7630 1X and Alpha CF into one great-tasting, non-drowsy, multi-action cold and flu formula. The delicious, convenient tablets are easy to pack and carry with you, so you can take them at a moments notice. Plus, theyre safe for ages 6 and up. The chewable tablets are also available in berry flavor.


Suggested Use As a dietary supplement Chew or dissolve tablets in the mouth. Do not swallow whole. For best results, use at the first sign of symptoms and continue to use for an additional 48 hours after symptoms cease. Adults & children 12 years of age and older take 1 chewable tablet 4-5 times daily. Children 6-11 years of age take 1 chewable tablet 2-4 times daily. Children under 6 years of age consult a doctor. - Or as directed by your healthcare professional.


Supplement Facts


Serving Size 1 Chewable Tablet


Amount Per Serving% Daily Value***


Pelargonium sidoides 1X


Aconitum napellus 4X


Eucalyptus globulus 2X


Bryonia alba 4X


Eupatorium perfoliatum 2X


Gelsemium sempervirens 4X


Phosphorus 6X


Ipecacuanha 3X


***Percent Daily Values are based on a 2,000 calorie diet

Other Ingredientscitric acid, lactose, magnesium stearate, malic acid, maltodextrin, mannitol, natural orange flavor, stearic acid, sorbitol, xylitol.


WarningsKeep out of reach of children. As with all dietary supplements, consult your healthcare professional before use. See product label for more information.


Subscribe